Siddiqui, RuqaiyyahLloyd, DavidAlharbi, Ahmad M.Khan, Naveed Ahmed2025-04-182025-04-182024Siddiqui, R., Lloyd, D., Alharbi, A. M., & Khan, N. A. (2024). Emerging therapies against Naegleria fowleri. Expert Opinion on Orphan Drugs, 12(1), 41-49.2167-8707http://dx.doi.org/10.1080/21678707.2024.2383173https://hdl.handle.net/20.500.12713/7152Introduction Naegleria fowleri is a free-living protist pathogen. Given the opportunity, it can produce infection of the central nervous system. It is distressing that the brain-eating amoebae, Naegleria fowleri remains one of the lethal parasites resulting almost always in death, despite advances in antimicrobial chemotherapy and supportive care. Areas covered The overall aim is to present a timely review of our current understanding of emerging therapies and priorities. By searching bibliographic databases (PubMed) for the available peer-reviewed research literature, herein, we discuss current advances, challenges and opportunities pertinent in the development of therapeutic interventions. Expert opinion The prospect of exploring repurposed drugs in combination with nanotechnology and a theranostic approach to concurrently achieve diagnosis and drug delivery will offer promise in the rational development of effective therapies to counter N. folweri-associated fatal brain infections.eninfo:eu-repo/semantics/openAccessNaegleria FowleriBrain-Eating AmoebaCNS InfectionsFree-Living AmoebaeEmerging TherapiesArticle1214149WOS:0012823864000012-s2.0-85200272066Q410.1080/21678707.2024.2383173Q2